Today, on 27 May 2026, the annual general meeting was held in Chosa Oncology AB. A summary of the adopted resolutions follows below.

Resolution on adoption of accounts and distribution of the company’s profit

The annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet. The annual general meeting also resolved to distribute the company’s profit in accordance with the proposal from the board meaning that no dividends are paid and that available funds are carried forward.

Discharge from liability for the members of the board and the CEO

The annual general meeting resolved to discharge the members of the board and the CEO from liability for the financial year 2025.

Election of board members and auditor as well as remuneration for the board members and auditor

The annual general meeting resolved in accordance with the proposal from Buhl Krone Holding ApS (the "Proposer") to re-elect Ingrid Atteryd Heiman, Claus Frisenberg Pedersen, Ulla Hald Buhl, Morten Myrhøj and Fred R. Hirsch as ordinary board members. Ingrid Atteryd Heiman was re-elected as Chairman of the board. Neil Goldsmith had declined re-election.

Remuneration to the board shall be paid with SEK 150,000 to the Chairman of the board and with SEK 75,000 to each of the other board members. Board remuneration shall not be paid to Claus Frisenberg Pedersen and Ulla Hald Buhl.

Furthermore, the annual general meeting resolved, in accordance with the proposal from the Proposer, to re-elect Deloitte AB as auditor and that remuneration for the auditor shall be paid in accordance with customary norms and approved invoice. Deloitte AB has informed that Maria Ekelund will continue to be appointed as the responsible auditor.

Resolution on authorization regarding issues

The annual general meeting resolved, in accordance with the proposal from the board of directors, to authorize the board of directors, up until the next annual general meeting, at one or several occasions, with or without deviation from the shareholders’ preferential rights and with or without provisions regarding contribution in kind, set-off or other conditions, to issue shares, convertibles and/or warrants.

The reason why a deviation from the shareholders’ preferential rights should be possible is to enable the company to source working capital, to be able to execute acquisitions of companies or operating assets as well as to enable issues to industrial partners within the framework of partnerships and alliances. To the extent that the authorization is used for an issue with deviation from the shareholders’ preferential rights, the issue shall take place on market terms.

Lund on 27 May 2026

Chosa Oncology AB (publ)

For additional information, contact:
Peter Buhl Jensen, CEO
Peter@chosa.bio  
+ 45 21 60 89 22

This information was submitted for publication, through the agency of the contact person set out above, on 27 May 2026. 

CHOSA in short

CHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene expression–based biomarker that predicts response to platinum-based chemotherapy. By identifying patients most likely to benefit, CHOSA aims to improve outcomes and optimize treatment selection in cancer care.

About Cisplatin-DRP, a test to predict if cisplatin treatment is likely to be successful

CHOSA is focused on its Platin-DRP® drug response predictor, to which it holds worldwide rights. Platin-DRP is a validated test designed to help identify patients most likely to benefit from cis- and carboplatin treatment. Breast: Strong phase 2b data in metastatic breast cancer have shown that patients selected by DRP® responded better to treatment, had longer progression-free survival, and may also have achieved longer overall survival than patients identified as unlikely to respond well. Lung: Platin-DRP has also demonstrated its ability to predict the benefit of adjuvant cisplatin in lung cancer. Cisplatin treatment after surgery remains a gold standard that can improve cure rates, but doctors have not had a validated tool to identify which patients are most likely to benefit. This is where Platin-DRP may become a game changer, particularly in newer neoadjuvant settings where immunotherapy has shown high efficacy in combination with platinum doublets. Platin-DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to eliminate residual tumour cells. Patients with the 10% highest scores had a 3-year survival of 90%, whereas patients with the lowest 10% scores had a 3-year survival of only 40%¹. 

Immunotherapy Cisplatin and carboplatin have often been shown to activate the immune system, potentially making "cold" tumours more susceptible to PD-1 inhibitors. This synergy may be important not only in lung cancer, but also in breast cancer, bladder cancer and head & neck cancer. In the growing PD-1 inhibitor market, CHOSA’s approach may offer the ability to predict whether platin can provide synergy with PD-1 inhibition, potentially creating a meaningful advantage for treatment selection and future partners.

1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609 2) ESMO Open Volume 11, Supplement 3, 106773, April 2026

DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.